HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

(2012) Marcel Kool et al.   ACTA NEUROPATHOLOGICA

A Mouse Model of the Most Aggressive Subgroup of Human Medulloblastoma

(2012) Daisuke Kawauchi et al.   CANCER CELL

An Animal Model of MYC-Driven Medulloblastoma

(2012) Yanxin Pei et al.   CANCER CELL

Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials

(2012) D. A. Berry et al.   CLINICAL CANCER RESEARCH

HDAC inhibitors for the treatment of cutaneous T-cell lymphomas

(2012) Sophia Rangwala et al.   Future Medicinal Chemistry

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas

(2012) A. Kunkele et al.   NEURO-ONCOLOGY

Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma

(2012) Xiumei Zhao et al.   NEURO-ONCOLOGY

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma

(2011) Sarra L. Ryan et al.   ACTA NEUROPATHOLOGICA

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat

(2011) Till Milde et al.   ACTA NEUROPATHOLOGICA

Molecular subgroups of medulloblastoma: the current consensus

(2011) Michael D. Taylor et al.   ACTA NEUROPATHOLOGICA

p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease

(2011) Marco Gessi et al.   JOURNAL OF NEURO-ONCOLOGY

Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation

(2011) Sung-Keum Seo et al.   Journal of Thoracic Oncology

Low-Dose Valproic Acid Enhances Radiosensitivity of Prostate Cancer through Acetylated p53-Dependent Modulation of Mitochondrial Membrane Potential and Apoptosis

(2011) X. Chen et al.   MOLECULAR CANCER RESEARCH

Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation

(2011) S Häcker et al.   ONCOGENE

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

(2010) Dana Rathkopf et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth

(2010) T. Milde et al.   CLINICAL CANCER RESEARCH

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors

(2010) M. G. Fakih et al.   CLINICAL CANCER RESEARCH

Enhancement of Radiation Response in Osteosarcoma and Rhabomyosarcoma Cell Lines by Histone Deacetylase Inhibition

(2010) Claudia Blattmann et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in Medulloblastoma

(2010) Elke Pfaff et al.   JOURNAL OF CLINICAL ONCOLOGY

Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report

(2010) Maryam Fouladi et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome

(2010) Yoon-Jae Cho et al.   JOURNAL OF CLINICAL ONCOLOGY

Medulloblastoma Comprises Four Distinct Molecular Variants

(2010) Paul A. Northcott et al.   JOURNAL OF CLINICAL ONCOLOGY

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

(2010) O. Khan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells

(2009) Xufeng Chen et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

(2009) Susan Fotheringham et al.   CANCER CELL

Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and theMYCandMYCNLoci

(2009) Stefan Pfister et al.   JOURNAL OF CLINICAL ONCOLOGY

Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics

(2009) Sarah Fattet et al.   JOURNAL OF PATHOLOGY

High-throughput detection and multiplex identification of cell contaminations

(2009) M. Schmitt et al.   NUCLEIC ACIDS RESEARCH

Large cell/anaplastic medulloblastoma: Outcome according to myc status, histopathological, and clinical risk factors

(2009) Katja von Hoff et al.   PEDIATRIC BLOOD & CANCER

HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells

(2008) Dennis Wegener et al.   ANTI-CANCER DRUGS

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

(2008) W. Weichert et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase 8 in Neuroblastoma Tumorigenesis

(2008) I. Oehme et al.   CLINICAL CANCER RESEARCH

Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features

(2008) Marcel Kool et al.   PLoS One